Åukasz BuÅ,dak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3361626/publications.pdf

Version: 2024-02-01

471061 525886 33 747 17 27 citations h-index g-index papers 41 41 41 1294 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Metformin affects macrophages' phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages. Pharmacological Reports, 2014, 66, 418-429.	1.5	82
2	Shortâ€ŧerm exposure to 50 Hz ELF‣MF alters the cisplatinâ€ɨnduced oxidative response in AT478 murine squamous cell carcinoma cells. Bioelectromagnetics, 2012, 33, 641-651.	0.9	57
3	The Impact of Coffee and Its Selected Bioactive Compounds on the Development and Progression of Colorectal Cancer In Vivo and In Vitro. Molecules, 2018, 23, 3309.	1.7	55
4	Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: An in vitro study. Oncology Reports, 2013, 29, 771-778.	1.2	48
5	Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. Pharmacological Reports, 2016, 68, 329-337.	1.5	44
6	Fibrates in the management of atherogenic dyslipidemia. Expert Review of Cardiovascular Therapy, 2017, 15, 913-921.	0.6	39
7	Effects of ghrelin, leptin and melatonin on the levels of reactive oxygen species, antioxidant enzyme activity and viability of the HCT 116 human colorectal carcinoma cell line. Molecular Medicine Reports, 2015, 12, 2275-2282.	1.1	38
8	Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 1103-1115.	1.4	36
9	Benefits and risks of the treatment with fibrates––a comprehensive summary. Expert Review of Clinical Pharmacology, 2018, 11, 1099-1112.	1.3	34
10	Pleiotropic Effects of PCSK-9 Inhibitors. International Journal of Molecular Sciences, 2021, 22, 3144.	1.8	33
11	Bile bacterial flora and its <i>in vitro</i> resistance pattern in patients with acute cholangitis resulting from choledocholithiasis. Scandinavian Journal of Gastroenterology, 2011, 46, 925-930.	0.6	31
12	Significance of selected antioxidant enzymes in cancer cell progression. Polish Journal of Pathology, 2014, 3, 167-175.	0.1	31
13	Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 905-919.	1.4	26
14	Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 805-813.	0.3	25
15	Current and future trends in the lipid lowering therapy. Pharmacological Reports, 2016, 68, 737-747.	1.5	22
16	Insight into the Evolving Role of PCSK9. Metabolites, 2022, 12, 256.	1.3	21
17	Comparison of chosen activation markers of human monocytes/macrophages isolated from the peripheral blood of young and elderly volunteers. Pharmacological Reports, 2014, 66, 759-765.	1.5	18
18	Ambivalent effects of compound C (dorsomorphin) on inflammatory response in LPS-stimulated rat primary microglial cultures. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 381, 41-57.	1.4	17

#	Article	IF	Citations
19	CD4+ cells in autoimmune thyroid disease. Endokrynologia Polska, 2021, 72, 572-583.	0.3	14
20	Endocrine diseases as causes of secondary hyperlipidemia. Endokrynologia Polska, 2019, 70, 511-519.	0.3	12
21	Metformin reduces the expression of NADPH oxidase and increases the expression of antioxidative enzymes in human monocytes/macrophages cultured in vitro. Experimental and Therapeutic Medicine, 2016, 11, 1095-1103.	0.8	9
22	The impact of exenatide (a GLP‹1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Experimental and Therapeutic Medicine, 2019, 17, 2861-2869.	0.8	8
23	Qualityâ€ofâ€life assessment in the treatment of iatrogenic bile duct injuries: hepaticojejunostomy versus endâ€toâ€end biliary reconstructions. ANZ Journal of Surgery, 2012, 82, 923-927.	0.3	7
24	Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. European Journal of Pharmacology, 2014, 726, 96-108.	1.7	7
25	A Novel, Highly Selective RT-QPCR Method for Quantification of MSRV Using PNA Clamping Syncytin-1 (ERVWE1). Molecular Biotechnology, 2015, 57, 801-813.	1.3	7
26	Current status of inherited pancreatic cancer. Hereditary Cancer in Clinical Practice, 2022, 20, .	0.6	7
27	Cardiovascular Diseases—A Focus on Atherosclerosis, Its Prophylaxis, Complications and Recent Advancements in Therapies. International Journal of Molecular Sciences, 2022, 23, 4695.	1.8	5
28	The application of strand invasion phenomenon, directed by peptide nucleic acid (⟨scp⟩PNA⟨ scp⟩) and singleâ€stranded ⟨scp⟩DNA⟨ scp⟩ binding protein (⟨scp⟩SSB⟨ scp⟩) for the recognition of specific sequences of human endogenous retroviral ⟨scp⟩HERVâ€W⟨ scp⟩ family. Journal of Molecular Recognition, 2017, 30, e2600.	1.1	4
29	Monitoring the Transcriptional Activity of Human Endogenous Retroviral HERV-W Family Using PNA Strand Invasion into Double-Stranded DNA. Molecular Biotechnology, 2018, 60, 124-133.	1.3	3
30	Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin-secreting 1.1E7 cell line subjected to hyperglycemia and oxidative stress. Postepy Higieny I Medycyny Doswiadczalnej, 2022, 76, 16-23.	0.1	3
31	Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek [*] . Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 385-397.	0.1	2
32	The treatment of heterozygous familial hypercholesterolemia â€" a local perspective. Endokrynologia Polska, 2021, 72, 189-190.	0.3	1
33	Polyunsaturated fatty acids in reducing cardiovascular risk. Pediatria I Medycyna Rodzinna, 2021, 17, 27-35.	2.3	0